What SanBio does

SanBio is a Tokyo-headquartered regenerative medicine company developing and commercializing allogeneic cell therapies based on its proprietary SB623 platform — bone marrow-derived mesenchymal stem cells that undergo transient (non-integrating) genetic modification to enhance neuroregenerative capacity. Its lead product, AKUUGO Suspension for Intracranial Implantation (INN: vandefitemcel), received conditional and time-limited marketing approval from Japan's MHLW on July 31, 2024 for improvement of chronic motor paralysis following traumatic brain injury — described by the company as the world's first cell therapy to regenerate brain tissue. The product is positioned as a one-time per-treatment cryopreserved cell therapy, thawed and administered at specialist neurosurgery centers, with NHI drug price listing expected around May 2026 and commercial launch announced for May 21, 2026.

The company's revenue model is built around direct sales to specialist medical institutions (initially 5 trial sites scaling to ~30 qualified hospitals nationwide), distributed through a cold-chain specialty wholesaler (Suzuken Co., Ltd.) using a jointly patented R-SAT dosing-schedule and traceability system. Commercial manufacturing is outsourced to JCR Pharmaceuticals under a CDMO agreement signed January 31, 2025, while SanBio retains in-house packaging, labeling, and storage under a license obtained in 2022. Drug pricing follows Japan's cost-calculation method with an operating-profit multiplier of 0.5 and no usefulness premium; the price has not been publicly disclosed. SanBio's pipeline extends SB623 and the related MSC2 platform into chronic ischemic stroke (Japan Phase 2b/3 preparation with PMDA consultation underway), Alzheimer's-type dementia (joint research), retinal diseases in Greater China (OcuMension partnership), and esophageal regeneration (D&P Bioinnovations). No product revenue has been booked through FY2026 because the NHI drug price was unlisted; an FY2026 operating loss of approximately JPY 5.6 billion is forecast, with the prior fiscal year's capital raise of JPY 14.2 billion supporting commercialization and pipeline investment.

Name

SanBio

Legal name

SanBio Company Limited

Website

https://sanbio.com

Company type

Public

Founded year

2001

Operating status

Operating

Headcount range

11–50 employees

Short description

SanBio is a Japan-headquartered regenerative medicine company developing allogeneic mesenchymal stem cell therapies, with lead product AKUUGO (SB623) approved in Japan for chronic motor paralysis from traumatic brain injury and launching commercially in May 2026 to specialist hospitals.

Ownership category

akta.pro rank

Product category

Regenerative Medicine (Cell Therapy)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834)

akta.pro primary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

akta.pro secondary industries

Neural & Spinal Cord Regeneration (HLAAAGAI), Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG), Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC)

Keywords

• Regenerative cell therapy
• Allogeneic stem cell medicine
• Traumatic brain injury treatment
• Central nervous system therapy
• Cell therapy manufacturing

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Others

Revenue model

1. AKUUGO® product sales (cell therapy medicine): Sales of AKUUGO® (vandefitemcel / SB623) for improvement of chronic motor paralysis associated with traumatic brain injury, following conditional and time-limited approval in Japan (July 2024). NHI drug price listing expected around May 2026; commercial launch announced May 21, 2026. Revenue expected to be one-time / per-treatment dosing.
2. Future indication expansion (chronic ischemic stroke, hemorrhagic stroke, Alzheimer’s, ophthalmology): Pipeline expansion into chronic ischemic stroke (Japan Phase 2b/3 preparation, with PMDA consultation in current fiscal year), chronic cerebral infarction, Alzheimer's disease (joint research), and ophthalmology indications in Greater China (OcuMension partnership) — each representing additional future revenue streams from the SB623 / MSC2 platforms.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Core offering

SanBio develops, manufactures, and commercializes allogeneic regenerative cell therapy medicines based on its proprietary SB623 platform — bone marrow-derived mesenchymal stem cells modified to enhance neuroregenerative capacity and cryopreserved for off-the-shelf administration. Its flagship marketed product AKUUGO Suspension for Intracranial Implantation (vandefitemcel) is approved in Japan for improvement of chronic motor paralysis from traumatic brain injury and is sold per-treatment to specialist neurosurgery centers. The SB623 / MSC2 platforms are also being expanded into chronic ischemic stroke, Alzheimer's-type dementia, ophthalmology, and esophageal regeneration indications.

Product overview

SanBio Company Limited (サンバイオ株式会社) is a Japanese regenerative cell medicine company organized around a single core product platform — SB623-based allogeneic mesenchymal stem cell therapies — rather than a multi-product SaaS-style architecture. The flagship marketed product is AKUUGO Suspension for Intracranial Implantation (INN: vandefitemcel), derived from SB623, which received conditional and time-limited marketing approval in Japan in July 2024 for chronic motor paralysis from traumatic brain injury and was launched in May 2026. SB623 itself is the underlying pipeline asset that is also being extended into chronic ischemic stroke, Alzheimer's-type dementia, and (via partners) retinal and esophageal indications. Supporting the core platform are three internal technology pillars: (1) an allogeneic (donor-derived) scalable production model that enables cost-efficient mass manufacturing, (2) large-scale cell production technology refined over roughly ten years, and (3) a world-leading development team led by founding scientist Professor Hideyuki Okano of Keio University. SanBio's pipeline, leadership in CNS regenerative medicine, and Japan-first commercialization strategy are tightly coupled to the SB623/AKUUGO platform.

Differentiator

Problem solved

Functional benefit

Brands

• AKUUGO: Japan-approved regenerative cell therapy product (based on SB623 allogeneic bone marrow-derived modified mesenchymal stem cells) indicated for chronic motor deficits secondary to traumatic brain injury.

Products and services

• AKUUGO Suspension for Intracranial Implantation (アクーゴ脳内移植用注 / INN: vandefitemcel) SanBio's lead regenerative cell therapy medicine, an allogeneic product based on SB623 (temporarily gene-modified bone marrow-derived mesenchymal stem cells) for intracranial implantation. Indicated for improvement of chronic motor paralysis associated with traumatic brain injury (TBI). Sold per-treatment to specialist neurosurgery centers under Japan's NHI reimbursement system.
• SB623 (vandefitemcel) platform Proprietary Cell Therapy Medicine (MSC implantation) made from modified and cultured adult bone marrow-derived mesenchymal stem cells that undergo temporary genetic modification. The underlying pipeline asset for AKUUGO and indication expansion into chronic ischemic stroke, Alzheimer's-type dementia, retinal diseases, and other CNS indications.
• SB623 for Chronic Ischemic Stroke Indication expansion program for SB623 targeting chronic ischemic stroke. Phase 2b additional analyses completed in the U.S.; Japan domestic chronic cerebral infarction program in trial-design rebuilding stage with PMDA consultations planned for the current fiscal year.
• SB623 for Alzheimer's-Type Dementia Joint research program exploring SB623 in Alzheimer's-type dementia, expanding the regenerative cell therapy platform into neurodegenerative disease indications.
• SB623 for Retinal Diseases (with OcuMension) Joint development with OcuMension (Hong Kong) Limited for R&D and commercialization of regenerative cell medicines in ophthalmology (retinal diseases including age-related macular degeneration and retinitis pigmentosa) in Greater China.
• MSC2 Esophageal Regeneration Implant (with D&P Bioinnovations) Business partnership with D&P Bioinnovations, Inc. for development and commercialization of a medical device implant utilizing MSC2 cells for regeneration of esophageal tissue in humans.

Quantifiable outcome

• STEMTRA Phase 2: 8.3-point improvement in FMMS at 24 weeks (SB623) vs 2.3 (control), p=0.040; 39.1% of SB623 patients achieved ≥10-point FMMS improvement vs 6.7% of controls (p=0.039).
• +2 more outcomes

Named customers1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Partnerships

Nine partnerships are on record, tiered minor, core / flagship, supportive, core and historical.

• Site-Fact Co., Ltd. (株式会社サイト-ファクト)minorImplementation/ SI/ Consulting Partner · 3 December 2025Basic agreement signed September 19, 2024 and basic outsourcing agreement for cell characterization analysis signed December 3, 2025. Site-Fact provides cell-property analytical services supporting SanBio's manufacturing and quality control work.
• JCR Pharmaceuticals Co., Ltd. (JCRファーマ株式会社)core / flagshipOEM/ Whitelabel/ Licensing Partner · 31 January 2025Contract manufacturing services agreement signed January 31, 2025 for trial production of AKUUGO® in preparation for commercial supply. JCR is the contracted CDMO for AKUUGO commercial manufacturing, allowing SanBio to scale up production while maintaining its own in-house packaging/labeling/storage facility.
• Suzuken Co., Ltd. (株式会社スズケン)core / flagshipChannel Partner/ Reseller/ Distributor · 9 May 2022Co-developed the R-SAT (Regenerative-medicine System for Administration Timing) distribution management and dosing-schedule support system for regenerative medicine products, with the patent granted in May 2022. Suzuken serves as the specialty pharmaceutical distribution partner for AKUUGO®, providing cold-chain logistics, traceability, and dosing-schedule support.
• D&P Bioinnovations, Inc.minorStrategic or Co-development Partner · 16 November 2021Business partnership (announced November 16, 2021) for the development and commercialization of a regenerative medical-device implant using MSC2 cells for esophageal tissue regeneration in humans.
• National TBI Registry Coalition (NTRC)supportiveGTM or Marketing Partner · 1 January 2021SanBio joined the U.S. National TBI Registry Coalition (NTRC) as a founding member organization in December 2021, supporting TBI awareness and registry activities relevant to its commercial indication.
• OcuMension (Hong Kong) LimitedcoreStrategic or Co-development Partner · 1 January 2020Business alliance agreement signed in 2020 for R&D and commercialization of regenerative cell medicines in ophthalmology indications in Greater China. Listed on SanBio's pipeline as a joint-development partner.
• Teijin Limited (former exclusive licensee)historicalOEM/ Whitelabel/ Licensing Partner · 1 October 2009Originally granted Teijin an exclusive license for SB623 in stroke in Japan (October 2009). The licensing agreement was mutually terminated in 2018, with SanBio regaining full rights. Top 10 shareholder as of January 31, 2023 with 992,477 shares (1.5%).
• Dainippon Sumitomo Pharma (now Sumitomo Pharma) — former partnerhistoricalStrategic or Co-development PartnerSigned option agreement (Sept 2010) and joint development & license agreement (June 2014) for SB623 in chronic stroke in the U.S. and Canada. Agreement was terminated in 2019.
• University of California, Stanford University, Keio University, and other academic collaboratorssupportiveStrategic or Co-development PartnerClinical and research collaborations including with Dr. Gary Steinberg (Stanford) for the SB623 stroke Phase 1/2a, Dr. Hideyuki Okano (Keio University) as founding scientist, and Keio University Hospital Clinical and Translational Research Center for regenerative-medicine seminars.

Scale indicators12 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Mesoblast Limited: Global commercial-stage allogeneic cellular medicines company (remestemcel-L, Ryoncil). Comparable in allogeneic MSC platform, large-scale manufacturing of living cells, and pursuit of regenerative medicine regulatory designations (RMAT, Sakigake) across multiple inflammatory and immune indications.
• Pluristem Therapeutics: Israel-based developer of allogeneic placenta-derived MSC therapies (PLX-PAD, PLX-R18). Directly comparable business model using off-the-shelf, scalable cell therapy platforms targeting regenerative indications; both companies have historically pursued partnerships with Japanese pharma and conditional-style approval pathways.
• Athersys, Inc. U.S.-based clinical-stage biotech developing MultiStem, an allogeneic bone-marrow-derived MSC therapy for stroke and other indications. Directly comparable in allogeneic MSC platform technology and CNS focus, though Athersys has faced clinical and financial setbacks.
• BrainStorm Cell Therapeutics: Clinical-stage developer of NurOwn, an autologous MSC-based cell therapy for neurodegenerative diseases (ALS, MS). Comparable in MSC cell therapy development for CNS indications and in clinical-stage execution challenges.
• Healios K.K. Japanese regenerative medicine company developing allogeneic stem cell therapies (HLCM051 for acute respiratory distress, HLCN061 for retinal diseases). Closest Japanese direct peer — same regulatory regime, similar small-cap TSE Growth Market profile, and parallel use of conditional approval pathways for cell therapies.
• Helixmith Co., Ltd. Korea/U.S.-based developer of Engensis (donor-derived cell therapy gene medicine) for diabetic neuropathy and other indications. Comparable as an Asian-headquartered allogeneic cell therapy developer pursuing U.S. and Asian regulatory pathways for regenerative indications.
• Cynata Therapeutics: Australia-based developer of Cymerus™, an iPSC-derived allogeneic MSC platform for inflammatory and immunologic conditions. Comparable in next-generation allogeneic scalable MSC manufacturing and global clinical development strategy.

Emerging players

• OcuMension Therapeutics: Hong Kong-based ophthalmology biotech and SanBio's Greater China development/commercialization partner for SB623 in retinal indications (2020 alliance). Adjacent comparable as an emerging cell-therapy-adjacent player in ophthalmology indications in the same SanBio pipeline.

Broad incumbents

• JCR Pharmaceuticals Co., Ltd. Japanese specialty biopharma and SanBio's CDMO partner for AKUUGO commercial manufacturing (Jan 2025 agreement). Overlaps with SanBio in regenerative medicine and biologic manufacturing, but JCR is a much larger established player with multiple approved products (e.g., JCR-developed regenerative medicines) and broader biopharma portfolio.
• Sumitomo Pharma Co., Ltd. Large Japanese pharma with a regenerative-medicine CNS franchise (e.g., stem cell-derived Parkinson's therapy with RVT-802/STEMCELL). Comparable as a Japan-based large pharma pursuing regenerative CNS therapies; previously partnered with SanBio on SB623 chronic stroke (terminated 2019).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=MSq8aNMmci0
• LinkedInlinkedin.com/company/sanbio

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Subsidiaries2 records

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SanBio